Effects of Nocturnal Non-invasive Ventilation on Energy Expenditure in Patients With Severe Chronic Obstructive Pulmonary Disease
Launched by SCHÖN KLINIK BERCHTESGADENER LAND · Oct 10, 2013
Trial Information
Current as of June 10, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria for Intervention group:
- • chronic obstructive pulmonary disease stage IV
- • indication for the use of a nocturnal non-invasive ventilation (according to the German guidelines Schoenhofer et al. 2008)
- • patient has not yet used non-invasive ventilation at all or inadequately (less than 3 hours per day)
- Exclusion Criteria for Intervention group:
- • acute exacerbation of chronic obstructive pulmonary disease
- • severe heart failure
- • body-mass-index \>35 m²/kg
- • fever
- Inclusion Criteria for control group:
- • chronic obstructive pulmonary disease stage IV (- healthy volunteers are also eligible for the sub-trial of this study to validate night movement accuracy of an activity monitor)
- Exclusion Criteria for control group:
- • acute exacerbation of chronic obstructive pulmonary disease
- • indication for the use of a non-invasive ventilation
- • severe heart failure
- • body-mass-index \>35 m²/kg
- • fever
About Schön Klinik Berchtesgadener Land
Schön Klinik Berchtesgadener Land is a leading healthcare institution specializing in orthopedic and rehabilitation medicine, located in the picturesque Berchtesgaden region of Germany. Renowned for its patient-centered approach, the clinic combines state-of-the-art medical technology with a holistic treatment philosophy, aiming to enhance recovery and improve the quality of life for its patients. As a clinical trial sponsor, Schön Klinik Berchtesgadener Land is committed to advancing medical research and innovation, conducting rigorous studies that contribute to the development of effective therapeutic solutions in musculoskeletal health and beyond. The institution fosters collaborations with academic and industry partners to ensure the highest standards of clinical research and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Schoenau Am Koenigssee, Bavaria, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials